Document is current
Any future updates will be listed below
-
Authors
Kobiela, Adrian
Klimczuk, Mikołaj
Serafin, Paweł Kamil
Kitowska, Kamila
Biernacka, Anna
Abouali, Reza
de la Serna, Jorge Bernardino
Wang, Xinwen
Gajdowska, Felicja
Kosobucka, Aniela
Siedlar, Aleksandra Małgorzata
Hauer, Amandine
Hovhannisyan, Lilit
Bogucka, Aleksandra
Smits, Jos P. H.
van den Bogaard, Ellen H.
Sądej, Rafał
Ogg, Graham S.
Gutowska-Owsiak, Danuta
-
Funding
Funding for this research was provided by:
Biotechnology and Biological Sciences Research Council (BB/V019791/1)
Medical Research Council (MR/X013855/1)
Wellcome Trust (301619/Z/23/Z)
LEO Foundation grant (LF-OC-22-001056)
Past4Future grant (LSHM20043-HSGF)
NIHR Oxford Biomedical Research Centre
NIHR Clinical Research Network
Fundacja na rzecz Nauki Polskiej (POIR.04.04.00-00-21FA/16-00)
- License Information
-
More Information
Article History
Received: 20 February 2025
Accepted: 31 December 2025
First Online: 8 January 2026
Declarations
:
: Ethical approval for the study was obtained from the Independent Bioethics Committee for Scientific Research at the Medical University of Gdańsk (ethical approval number NKBBN/621–574/2020).
: Not applicable.
: GSO has served on advisory boards or holds consultancies or research grants with Eli Lilly, Novartis, Janssen, BMS and UCB Pharma, Regeneron/Sanofi, Roche, Anaptysbio. GSO has patent filed in the CD1a field. The other authors declare that they have no competing interests.
